Squarepoint’s Bionano Genomics BNGO Stock Holding History

Squarepoint’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-500	Closed	-$8.65K	–	4613
2024 Q4	$8.65K	Buy	+500	New	+$8.55K	﹤0.01%	4960

Other funds holding BNGO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

CCM

Coldstream Capital Management Bellevue, Washington $8.12B AUM 17.95% 1-Year Est. Return

Squarepoint's BNGO Position: Q2 2024 in Review

Squarepoint sold out of Bionano Genomics (BNGO) in Q2 2024, closing a stake of 336 shares — an estimated $22.4K sold.

Squarepoint first reported a position in BNGO in Q4 2020 and held it in 7 quarters. The position peaked at $2.04M in Q3 2021. 53 funds tracked by Wall St. Rank hold BNGO as of Q2 2024.

Squarepoint reported no remaining Bionano Genomics position as of Q2 2024 after selling out during the quarter.
Squarepoint sold 336 Bionano Genomics shares in Q2 2024, an estimated $22.4K.
Squarepoint first reported a position in Bionano Genomics in Q4 2020 and held it in 7 quarters.
Squarepoint's Bionano Genomics position peaked at $2.04M in Q3 2021.
53 funds tracked by Wall St. Rank held Bionano Genomics as of Q2 2024.

Based on Squarepoint's 13F filing for Q2 2024, filed 14 Aug 2024.